Tuesday, August 30, 2011

Image Apoptosis In Vivo! NIR-FLIVO Tracers Now Available

ImmunoChemistry Technologies, LLC is pleased to announce the launch of two new tracers for non-invasive in vivo optical imaging of apoptosis. NIR-FLIVO™ 690 and NIR-FLIVO™ 747 in vivo apoptosis tracers and free dye control reagents are now available from ImmunoChemistry Technologies at introductory pricing.


Learn more about the new NIR-FLIVO in vivo apoptosis tracers at
www.immunochemistry.com/new-near-infrared-tracers-non-invasive-vivo-imaging-apoptosis.

The FLIVO™ product line utilizes proprietary in vivo tracer technology for apoptosis detection in live animal models.  The non-toxic, cell-permeant FLIVO™ reagents specifically label apoptotic cells in vivo for analysis with fluorescence detection methods. These tracers, aka fluorescent probes, have been successfully used in a range of animal models to assess apoptosis as a result of a treatment or biological condition.

The new NIR-FLIVO™ apoptosis tracers utilize the near-infrared fluorescent labels DyLight® 690 and DyLight® 747 for noninvasive detection with whole animal imaging systems. Additionally, visible FLIVO™ tracers are available with carboxyfluorescein (FAM, green) or sulforhodamine-B (SR, red) labels for ex vivo optical imaging or flow cytometric analysis of histological samples.

These first-generation FLIVO tracers (FAM-FLIVO, SR-FLIVO) have proven to be useful for in vivo labeling of apoptotic cells, such as detecting apoptosis in vivo in ischemic hepatic tissue and in vivo labeling of cutaneous or shallow subcutaneous tumor growth entities. These shorter spectral-wavelength dyes tend to perform optimally when using ex vivo analysis methods.

Read more at www.immunochemistry.com/products/fluorescent-detection-reagents-for-apoptosis-and-protease-detection/in-vivo-apoptosis.html.

Join our mailing list to receive future product release updates.


FLIVO™ is a trademark of ImmunoChemistry Technologies, LLC.
DyLight® is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.

No comments:

Post a Comment